MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer. Qu T, Song L, Xu J, Lu X, et al. Cancer Res 2025 May 14. doi: 10.1158/0008-5472.CAN-23-3748.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Qu T, Song L, Xu J, Lu X, et al. MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer. Cancer Res 2025 May 14. doi: 10.1158/0008-5472.CAN-23-3748.
PMID: 40366631